Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma
Oncology · 2024 · 102 (3) · 252-259
DOI: 10.1159/000533860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, online erschienen am 14.09.2023. Verfasst von Reio Ueta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Nivolumab. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Patients with the head and neck squamous cell carcinoma (SCC) are often treated with immune checkpoint inhibitors (ICIs). Recently, antibiotic intake was reported to lower the efficacy of ICIs in patients with several types of cancers. However, it is unclear if antibiotics affect the efficacy of ICIs in patients with head and neck SCC. We retrospectively assessed the influence of antibiotics on the treatment efficacy of nivolumab, an ICI, in patients with head and neck SCC.
Methods
We reviewed the medical records of patients with head and neck SCC treated with nivolumab at the Department of Medical Oncology, Tohoku University Hospital, between 2017 and 2021. Patients who received oral or intravenous antibiotics from a month before the day of nivolumab initiation to the day of the first imaging evaluation of ICI efficacy were assigned to the antibiotic-treated group. The remaining patients were assigned to the antibiotic-untreated group. The response rate (RR), progression-free survival (PFS), and overall survival time (OS) of both groups were compared.
Results
Forty-five patients were assigned to the antibiotic-treated group and 19 to the antibiotic-untreated group. The RR, median PFS, and median OS of the antibiotic-treated group were 23.7%, 3.2 months (95% confidential interval [CI]: 2.0–4.1), and 8.4 months (95% CI: 5.3–15.1) and those of the antibiotic-untreated group were 42.1%, 5.8 months (95% CI: 2.3–16.7), and 18.4 months (95% CI: 6.2–23.1), respectively. The PFS of the antibiotic-untreated group was significantly longer than that of the antibiotic-treated group.
Conclusion
Our findings indicate that antibiotic treatment significantly shortens the PFS with nivolumab therapy in patients with head and neck SCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
- Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan, hiroo.imai.d8@tohoku.ac.jp.
- Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan, hiroo.imai.d8@tohoku.ac.jp.
Zitieren
APA
Ueta, R., Imai, H., Saijo, K., Kawamura, Y., Kodera, S., Komine, K., Ouchi, K., Kasahara, Y., Taniguchi, S., Yoshida, Y., Sasaki, K., Shirota, H., Takahashi, M., & Ishioka, C. (2024). Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma. Oncology, 102(3), 252-259. https://doi.org/10.1159/000533860
Vancouver
Ueta R, Imai H, Saijo K, Kawamura Y, Kodera S, Komine K, et al. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma. Oncology. 2024;102(3):252-259. doi:10.1159/000533860
BibTeX
@article{Ueta2024,
author = {Ueta, Reio and Imai, Hiroo and Saijo, Ken and Kawamura, Yoshifumi and Kodera, Shuto and Komine, Keigo and Ouchi, Kota and Kasahara, Yuki and Taniguchi, Sakura and Yoshida, Yuya and Sasaki, Keiju and Shirota, Hidekazu and Takahashi, Masanobu and Ishioka, Chikashi},
title = {Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma},
journal = {Oncology},
year = {2024},
volume = {102},
number = {3},
pages = {252--259},
doi = {10.1159/000533860}
}
EUVIMED